Silence Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions GBP

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Silence Therapeutics plc (SLN) - Annual data in millions GBP
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-36.19-50.31-47.37-45.86-36.04-22.87-20.53
Depreciation & Amortization0.590.500.600.580.500.480.00
Deferred Income Tax0.850.960.695.953.020.000.00
Stock Based Compensation13.0316.2712.6911.656.000.000.00
Change in Working Capital-33.02-11.66-19.4052.4318.6621.090.91
Change in Accounts Receivable-0.900.39-0.7237.21-40.010.000.00
Change in Accounts Payable0.00-0.472.023.251.780.000.00
Change in Other Working Capital-32.12-1.80-0.280.06-5.090.000.00
Other Operating Activities-12.8919.90-0.280.06-4.670.14-0.05
Net Cash from Operating Activities-67.64-39.35-57.049.19-10.781.73-16.76
Investing Activities
Capital Expenditures-0.210.05-0.55-1.800.510.01-0.13
Acquisitions0.00-20.67-16.130.000.000.000.00
Purchases of Investments-139.17-25.77-19.9513.5413.650.000.00
Sales/Maturities of Investments0.0045.12-0.3713.5010.00-15.00-4.68
Other Investing Activities117.410.960.020.01-0.540.000.00
Net Cash from Investing Activities-21.97-19.75-20.5011.719.62-15.02-4.83
Financing Activities
Debt Repayment0.00-0.17-0.23-0.28-0.400.000.00
Common Stock Issued142.0925.3352.5841.7315.835.270.34
Net Cash from Financing Activities142.0961.3452.5841.4515.435.270.34
Summary
Effect of Forex Changes on Cash0.06-3.02-8.12-0.14-0.340.040.00
Net Change in Cash52.542.24-24.9662.3413.93-7.98-21.25
Cash at Beginning of Period68.7954.8299.3537.0513.5221.4942.75
Cash at End of Period121.3354.0366.2799.2527.4513.5221.49
Free Cash Flow-67.85-39.40-57.597.39-10.781.73-16.95
Supplemental Disclosures
Income Taxes Paid0.430.800.000.00-4.120.000.00